Preoperative therapy with chemotherapy and the HER@-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER@-positive ( HER@ + ) breast cancers but traditional methods of measuring HER@ expression do not accurately stratify patients for likelihood of response .